BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aptuit LLC Offers Fast, Prelimary Hippocampal Screening Studies for CNS Drugs


3/27/2013 9:41:55 AM

Greenwich, CT, March 26, 2013 – Aptuit announces that it offers fast screenings of synaptic activity on hippocampal slices for clients who are focused on the central nervous system (CNS) therapeutic area.

Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, said Aptuit provides an expeditious way to obtain a preliminary understanding of a compound’s effect on hippocampal synaptic activity. He added, “In a short period, the quality data that we secure assists clients in the assessment of the desired effect of their compounds with both mechanism of action and safety profile results. We are in position to follow through with further experiments as needed.”

Mr. Needleman stated, “In place of the customary 14-day required to perform the studies, Aptuit can complete preliminary hippocampal screening studies in just five days. And, while hippocampal screening studies may be available from other sources, Aptuit employs two tested concentrations rather than the single concentration that is more common.”

Dr. Annarosa Ugolini, Principal Scientist in the Electrophysiology Laboratory at The Aptuit Center for Drug Discovery & Development in Verona, Italy, said that Aptuit is able to evaluate potential compound effect on cognitive brain circuits. She further explained, “We evaluate effects of the compound in two tested concentrations on the synaptic activity of pyramidal neurons in acute hippocampal slices. We study basal synaptic transmission, short term plasticity and the long term plasticity. When an effect is detected, we can be much more succinct in proposing further studies when they are needed. Moreover, in the same hippocampal preparation we can also evaluate side effects, such as the manifestation of epileptogenic activity after compound application.”

Aptuit’s experimental methods feature a semi-automated system of extracellular concurrent and independent recordings, leading to increased throughput and reduced animal use; rat or mice acute slices; and three tested slices/compound concentration.

Mr. Needleman concluded, “Since time and cost are primary client concerns, these in vitro electrophysiological assessments provide a more rapid solution to the investigative process, providing an accurate picture early on in the evaluation of specific compound activity in the central nervous system.”

For more information, please contact Maria Garvey at Delfino Marketing either by phone at 914-747-1400 or by email: maria@delfino.com.

Aptuit LLC provides the most complete set of integrated early to mid-phase development services in the pharmaceutical industry. Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Sterile Fill Finish & Formulation Development, Oral Dosage Form Development & Manufacture, Clinical Sciences, Consulting and Aptuit INDiGOÒ (a program that accelerates drug development) are offered as stand alone or integrated services. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains five global facilities with approximately 800 employees in Europe and the United States, and has a strategic relationship with Laurus Labs in India. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.

For more information about Aptuit, visit www.aptuit.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES